Novo Nordisk Confronts a Squeeze From All Sides as Buybacks Meet a Pricing Onslaught
Novo Nordisk accelerates $4.2B buyback as stock trades near half 52-week high, while Trump administration expands TrumpRx with…
Novo Nordisk’s AI Alliance Confronts Asian Market Pressures
Novo Nordisk partners with OpenAI for drug discovery but faces a fierce price war in key Asian markets…